322 related articles for article (PubMed ID: 25811862)
1. Associations of fibroblast growth factor-23 with markers of inflammation, insulin resistance and obesity in adults.
Hanks LJ; Casazza K; Judd SE; Jenny NS; Gutiérrez OM
PLoS One; 2015; 10(3):e0122885. PubMed ID: 25811862
[TBL] [Abstract][Full Text] [Related]
2. Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease.
Munoz Mendoza J; Isakova T; Cai X; Bayes LY; Faul C; Scialla JJ; Lash JP; Chen J; He J; Navaneethan S; Negrea L; Rosas SE; Kretzler M; Nessel L; Xie D; Anderson AH; Raj DS; Wolf M;
Kidney Int; 2017 Mar; 91(3):711-719. PubMed ID: 28017325
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast growth factor-23 is a strong predictor of insulin resistance among chronic kidney disease patients.
Fayed A; El Nokeety MM; Heikal AA; Abdulazim DO; Naguib MM; Sharaf El Din UAA;
Ren Fail; 2018 Nov; 40(1):226-230. PubMed ID: 29619868
[TBL] [Abstract][Full Text] [Related]
4. Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance.
Axelsson J; Bergsten A; Qureshi AR; Heimbürger O; Bárány P; Lönnqvist F; Lindholm B; Nordfors L; Alvestrand A; Stenvinkel P
Kidney Int; 2006 Feb; 69(3):596-604. PubMed ID: 16395259
[TBL] [Abstract][Full Text] [Related]
5. Associations of Fibroblast Growth Factor 23 with Markers of Inflammation and Leukocyte Transmigration in Chronic Kidney Disease.
Wallquist C; Mansouri L; Norrbäck M; Hylander B; Jacobson SH; Larsson TE; Lundahl J
Nephron; 2018; 138(4):287-295. PubMed ID: 29301137
[TBL] [Abstract][Full Text] [Related]
6. Inflammation but not obesity or insulin resistance is associated with increased plasma fibroblast growth factor 23 concentration in the elderly.
Holecki M; Chudek J; Owczarek A; Olszanecka-Glinianowicz M; Bożentowicz-Wikarek M; Duława J; Mossakowska M; Zdrojewski T; Skalska A; Więcek A
Clin Endocrinol (Oxf); 2015 Jun; 82(6):900-9. PubMed ID: 25736796
[TBL] [Abstract][Full Text] [Related]
7. Association of Fibroblast Growth Factor 23 With Risk of Incident Coronary Heart Disease in Community-Living Adults.
Panwar B; Judd SE; Wadley VG; Jenny NS; Howard VJ; Safford MM; Gutiérrez OM
JAMA Cardiol; 2018 Apr; 3(4):318-325. PubMed ID: 29516098
[TBL] [Abstract][Full Text] [Related]
8. Associations of 25-hydroxyvitamin D with markers of inflammation, insulin resistance and obesity in black and white community-dwelling adults.
Jackson JL; Judd SE; Panwar B; Howard VJ; Wadley VG; Jenny NS; Gutiérrez OM
J Clin Transl Endocrinol; 2016 Sep; 5():21-25. PubMed ID: 27833859
[TBL] [Abstract][Full Text] [Related]
9. Impact of fractional phosphate excretion on the relation of FGF23 with outcome in CKD patients.
Bech AP; Bouma-de Krijger A; van Zuilen AD; Bots ML; van den Brand JA; Blankestijn PJ; Wetzels JF; Vervloet MG
J Nephrol; 2015 Aug; 28(4):477-84. PubMed ID: 25700931
[TBL] [Abstract][Full Text] [Related]
10. Phosphate, fibroblast growth factor 23 and retinopathy in chronic kidney disease: the Chronic Renal Insufficiency Cohort Study.
Mehta R; Ying GS; Houston S; Isakova T; Nessel L; Ojo A; Go A; Lash J; Kusek J; Grunwald J; Wolf M;
Nephrol Dial Transplant; 2015 Sep; 30(9):1534-41. PubMed ID: 25910495
[TBL] [Abstract][Full Text] [Related]
11. Insulin resistance, inflammatory biomarkers, and adipokines in patients with chronic kidney disease: effects of angiotensin II blockade.
de Vinuesa SG; Goicoechea M; Kanter J; Puerta M; Cachofeiro V; Lahera V; Gómez-Campderá F; Luño J
J Am Soc Nephrol; 2006 Dec; 17(12 Suppl 3):S206-12. PubMed ID: 17130263
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast growth factor 23 and Inflammation in CKD.
Munoz Mendoza J; Isakova T; Ricardo AC; Xie H; Navaneethan SD; Anderson AH; Bazzano LA; Xie D; Kretzler M; Nessel L; Hamm LL; Negrea L; Leonard MB; Raj D; Wolf M;
Clin J Am Soc Nephrol; 2012 Jul; 7(7):1155-62. PubMed ID: 22554719
[TBL] [Abstract][Full Text] [Related]
13. Resistin is Associated with Inflammation and Renal Function, but not with Insulin Resistance in Type 2 Diabetes.
Rzepa Ł; Peller M; Eyileten C; Rosiak M; Kondracka A; Mirowska-Guzel D; Opolski G; Filipiak KJ; Postuła M; Kapłon-Cieslicka A
Horm Metab Res; 2021 Jul; 53(7):478-484. PubMed ID: 34169498
[TBL] [Abstract][Full Text] [Related]
14. Insulin resistance is associated with Fibroblast Growth Factor-23 in stage 3-5 chronic kidney disease patients.
Garland JS; Holden RM; Ross R; Adams MA; Nolan RL; Hopman WM; Morton AR
J Diabetes Complications; 2014; 28(1):61-5. PubMed ID: 24125760
[TBL] [Abstract][Full Text] [Related]
15. High fibroblast growth factor 23 is associated with coronary calcification in patients with high adiponectin: analysis from the KoreaN cohort study for Outcome in patients With Chronic Kidney Disease (KNOW-CKD) study.
Hyun YY; Kim H; Oh YK; Oh KH; Ahn C; Sung SA; Choi KH; Kim SW; Lee KB
Nephrol Dial Transplant; 2019 Jan; 34(1):123-129. PubMed ID: 29701806
[TBL] [Abstract][Full Text] [Related]
16. Relation between Red Cell Distribution Width and Fibroblast Growth Factor 23 Cleaving in Patients with Chronic Kidney Disease and Heart Failure.
van Breda F; Emans ME; van der Putten K; Braam B; van Ittersum FJ; Kraaijenhagen RJ; de Borst MH; Vervloet M; Gaillard CA
PLoS One; 2015; 10(6):e0128994. PubMed ID: 26079688
[TBL] [Abstract][Full Text] [Related]
17. Fibroblast growth factor 23, left ventricular mass, and left ventricular hypertrophy in community-dwelling older adults.
Jovanovich A; Ix JH; Gottdiener J; McFann K; Katz R; Kestenbaum B; de Boer IH; Sarnak M; Shlipak MG; Mukamal KJ; Siscovick D; Chonchol M
Atherosclerosis; 2013 Nov; 231(1):114-9. PubMed ID: 24125420
[TBL] [Abstract][Full Text] [Related]
18. Association of homeostasis model assessment of insulin resistance, adiponectin, and low-grade inflammation with the course of the metabolic syndrome.
Ding Y; Li S; Ma RL; Guo H; Zhang J; Zhang M; Liu J; Guo S
Clin Biochem; 2015 May; 48(7-8):503-7. PubMed ID: 25700597
[TBL] [Abstract][Full Text] [Related]
19. Synergistic Effect of Inflammatory Cytokines and Body Adiposity on Insulin Resistance and Endothelial Markers in Patients With Stages 3-5 Chronic Kidney Disease.
Barreto Silva MI; Klein MRST; Cardoso ÉS; Costa MS; Martins CJM; Bregman R
J Ren Nutr; 2020 Jan; 30(1):36-45. PubMed ID: 30956091
[TBL] [Abstract][Full Text] [Related]
20. Effect of pioglitazone on serum FGF23 levels among patients with diabetic kidney disease: a randomized controlled trial.
Triwatana W; Satirapoj B; Supasyndh O; Nata N
Int Urol Nephrol; 2023 May; 55(5):1255-1262. PubMed ID: 36441433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
